Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 2-(acetylamino)-3-methoxy-n-(phenylmethyl)-, (2r)-
2. Add-234037
3. Ertosamide
4. Harkoseride
5. Spm-927
1. 175481-36-4
2. Erlosamide
3. Vimpat
4. (r)-2-acetamido-n-benzyl-3-methoxypropanamide
5. Harkoseride
6. Spm 927
7. Spm-927
8. (2r)-2-acetamido-n-benzyl-3-methoxypropanamide
9. (r)-lacosamide 1
10. Propanamide, 2-(acetylamino)-3-methoxy-n-(phenylmethyl)-, (2r)-
11. Add 243037
12. Add-234037
13. Chembl58323
14. 563ks2pqy5
15. Add-243037
16. Erlosamide [inn]
17. Ncgc00253740-01
18. (r)-2-acetamido-n-benzyl-3-methoxypropionamide.
19. (r)-2-acetylamino-n-benzyl-3-methoxy-propionamide
20. Lacosamide [usan]
21. (+)-(2r)-2-(acetylamino)-n-benzyl-3-methoxypropanamide
22. Ertosamide
23. Add 234037
24. Harkeroside
25. Unii-563ks2pqy5
26. Lacosamide [usan:inn:ban]
27. Lacosamide Cv
28. Spm-929
29. Lacosamide Racemate
30. Lacosamide- Bio-x
31. (2r)-2-(acetylamino)-n-benzyl-3-methoxypropanamide
32. Vimpat (tn)
33. Lacosamide [mi]
34. Lacosamide [inn]
35. Lacosamide [jan]
36. Lacosamide [vandf]
37. Lacosamide [mart.]
38. (r)-n-benzyl-2-acetamido-3-methoxypropionamide
39. Dsstox_cid_31455
40. Dsstox_rid_97341
41. Lacosamide [who-dd]
42. Dsstox_gsid_57666
43. Schembl35330
44. Lacosamide (jan/usan/inn)
45. Lacosamide [ema Epar]
46. Gtpl7472
47. Zinc7673
48. Dea No. 2746
49. Lacosamide Cv [usp-rs]
50. Dtxsid1057666
51. Lacosamide [orange Book]
52. Lacosamide [ep Monograph]
53. Chebi:135939
54. Lacosamide [usp Monograph]
55. Bcp02197
56. Tox21_113857
57. Bdbm50300204
58. Mfcd08272557
59. Akos005146274
60. Lacosamide 1.0 Mg/ml In Acetonitrile
61. Cs-0529
62. Db06218
63. Ks-1227
64. Ac-22750
65. Am808141
66. Bl164605
67. Hy-13015
68. A3897
69. Bb 0260890
70. Cas-175481-36-4
71. (r)-n-benzyl-2-acetamido-3-methoxypropanamide
72. D07299
73. (2r)-n-benzyl-2-acetamido-3-methoxypropanamide
74. (r)-2-acetamido-n-benzyl-3-methoxypropionamide
75. (r)-n-benzyl 2-acetamido-3-methoxypropionamide
76. (r)-n-benzyl 2-acetamido-3-methoxypropionamide,
77. Ab01559947-01
78. (2r)-2-acetylamino-n-benzyl-3-methoxypropanamide
79. (r)-2-acetylamino-n-benzyl-3-methoxypropionamide
80. 481l364
81. Ar-270/11402703
82. Q420077
83. Sr-01000942286
84. Sr-01000942286-1
85. (2r)-2-acetamido-3-methoxy-n-(phenylmethyl)propanamide
86. 2-(acetylamino)-3-methoxy-n-(phenylmethyl)-, (2r)-
87. Z1550648754
88. Lacosamide Solution, 1.0 Mg/ml In Acetonitrile, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 250.29 g/mol |
|---|---|
| Molecular Formula | C13H18N2O3 |
| XLogP3 | 0.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 250.13174244 g/mol |
| Monoisotopic Mass | 250.13174244 g/mol |
| Topological Polar Surface Area | 67.4 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 275 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Vimpat |
| PubMed Health | Lacosamide |
| Drug Classes | Anticonvulsant |
| Active Ingredient | Lacosamide |
| Dosage Form | Tablet; Solution |
| Route | Oral; Intravenous |
| Strength | 200mg/20ml (10mg/ml); 200mg; 150mg; 10mg/ml; 100mg; 50mg |
| Market Status | Prescription |
| Company | Ucb |
| 2 of 2 | |
|---|---|
| Drug Name | Vimpat |
| PubMed Health | Lacosamide |
| Drug Classes | Anticonvulsant |
| Active Ingredient | Lacosamide |
| Dosage Form | Tablet; Solution |
| Route | Oral; Intravenous |
| Strength | 200mg/20ml (10mg/ml); 200mg; 150mg; 10mg/ml; 100mg; 50mg |
| Market Status | Prescription |
| Company | Ucb |
Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
FDA Label
Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Lacosamide Accord is indicated as adjunctive therapy
in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Treatment of epilepsy with partial-onset seizures
Treatment of generalised epilepsy and epileptic syndromes
Lacosamide therapy is correlated with a decrease in seizure frequency. It should be noted that in group analyses, dosages above 400 mg/day do not appear to result in additional benefit.
N03AX18
N03AX18
N03AX18
N03AX18
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AX - Other antiepileptics
N03AX18 - Lacosamide
Absorption
Lacosamide has a negligible first pass effect with bioavailability of about 100%. The maximum Lacosamide plasma concentrations occur about 1-4 hours after oral administration, and the pharmacokinetics of Lacosamide are dose proportional. Food does not affect absorption.
Route of Elimination
Lacosamide is eliminated primarily from the systemic circulation by biotransformation and renal excretion.
Volume of Distribution
approximately 0.6 L/kg; thus close to the volume of total body water.
Clearance
95% recovered in the urine 0.5% in the feces
Lacosamide is a CYP2C19 substrate. The relative contribution of other CYP isoforms or non-CYP enzymes in the metabolism of lacosamide is not known. Primary compounds excreted were unchanged lacosamide (approximately 40% of the dose), its O-desmethyl metabolite (approximately 30%), and a structurally unknown polar fraction (~20%). The plasma exposure of the major human metabolite, O-desmethyl-lacosamide, is approximately 10% of that of lacosamide. This metabolite has no known pharmacological activity.
13 Hours
It is proposed that lacosamide's inhibition of sodium channels is responsible for analgesia. Lacosamide may be selective for inhibiting depolarized neurons rather than neurons with normal resting potentials. Pain and nociceptor hyperexcitability are associated with neural membrane depolarization. Lacosamide binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein which is expressed primarily in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. The role CRMP-2 of binding in seizure control is hasn't been elucidated.
Certificate Number : R0-CEP 2021-451 - Rev 01
Issue Date : 2023-05-16
Type : Chemical
Substance Number : 2992
Status : Valid
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38789
Submission : 2023-09-28
Status : Active
Type : II
Certificate Number : CEP 2023-365 - Rev 01
Issue Date : 2025-01-14
Type : Chemical
Substance Number : 2992
Status : Valid
NDC Package Code : 42765-060
Start Marketing Date : 2023-06-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-14
Pay. Date : 2012-10-25
DMF Number : 26381
Submission : 2012-09-27
Status : Active
Type : II
SNJ Labs: WHO-GMP certified API leader in India, specializing in bulk drugs & intermediates with unmatched expertise.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38789
Submission : 2023-09-28
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-14
Pay. Date : 2012-10-25
DMF Number : 26381
Submission : 2012-09-27
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-20
Pay. Date : 2012-11-02
DMF Number : 26349
Submission : 2012-09-07
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-03-13
Pay. Date : 2012-11-01
DMF Number : 26323
Submission : 2012-10-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-03-12
Pay. Date : 2012-10-25
DMF Number : 26313
Submission : 2012-08-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-03-01
Pay. Date : 2012-12-05
DMF Number : 26136
Submission : 2012-06-07
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-02-04
Pay. Date : 2012-11-20
DMF Number : 26270
Submission : 2012-07-21
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26250
Submission : 2012-10-26
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-01-08
Pay. Date : 2012-11-23
DMF Number : 26174
Submission : 2012-10-09
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Certificate Number : R0-CEP 2021-451 - Rev 01
Status : Valid
Issue Date : 2023-05-16
Type : Chemical
Substance Number : 2992
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Certificate Number : CEP 2023-365 - Rev 01
Status : Valid
Issue Date : 2025-01-14
Type : Chemical
Substance Number : 2992
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2019-041 - Rev 01
Status : Valid
Issue Date : 2024-03-05
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2019-184 - Rev 00
Status : Valid
Issue Date : 2022-03-29
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-437 - Rev 02
Status : Valid
Issue Date : 2023-07-27
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2020-107 - Rev 03
Status : Valid
Issue Date : 2024-05-02
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2021-147 - Rev 02
Status : Valid
Issue Date : 2024-02-22
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2019-049 - Rev 01
Status : Valid
Issue Date : 2022-08-12
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2022-236 - Rev 00
Status : Valid
Issue Date : 2023-11-27
Type : Chemical
Substance Number : 2992

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2020-283 - Rev 00
Status : Valid
Issue Date : 2021-10-28
Type : Chemical
Substance Number : 2992

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Registration Number : 306MF10100
Registrant's Address : 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad-500 032, ...
Initial Date of Registration : 2024-07-17
Latest Date of Registration : 2024-07-17

Registration Number : 306MF10110
Registrant's Address : 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad-500 018, Telang...
Initial Date of Registration : 2024-08-07
Latest Date of Registration : 2024-08-07

Registration Number : 306MF10102
Registrant's Address : Great Eastern Chambers, CBD Belapur, Navi Mumbai-400 614, India
Initial Date of Registration : 2024-07-17
Latest Date of Registration : 2024-07-17

Registration Number : 306MF10101
Registrant's Address : Plot No: C-24, Sanath Nagar Industrial Estate, Sanath Nagar, Hyderabad, Telangana, In...
Initial Date of Registration : 2024-07-17
Latest Date of Registration : 2024-07-17

Registration Number : 306MF10075
Registrant's Address : 2-7-1 Nihonbashi, Chuo-ku, Tokyo
Initial Date of Registration : 2024-06-06
Latest Date of Registration : 2024-06-06

Registration Number : 306MF10107
Registrant's Address : A43 2nd Floor, Prasanthi Towers, Road No 92, Jubilee Hills, Hyderabad, Telangana 5000...
Initial Date of Registration : 2024-07-31
Latest Date of Registration : 2024-07-31

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Seongwoo Chemical Co., Ltd.
Registration Date : 2016-04-29
Registration Number : Su4579-10-ND
Manufacturer Name : Alembic Pharmaceuticals Limi...
Manufacturer Address : Panelav, PO Tajpura, Taluka-Halol, District- Panchmahal - 389350, Gujarat State, Indi...

Registrant Name : Pharmaline Co., Ltd.
Registration Date : 2021-08-20
Registration Number : Su97-1-ND
Manufacturer Name : Divi's Laboratories Ltd.
Manufacturer Address : Unit-2, 531162, Chippada Village, Annavaram, Bheemunipatnam Mandal, Visakhapatnam Dis...

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2024-05-16
Registration Number : Su258-19-ND
Manufacturer Name : Emnar Pharma Pvt Ltd
Manufacturer Address : Unit-II, Plot No. 15, Jawaharlal Nehru Pharma City, Tadi (Village), Parawada Mandal, ...

Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2018-03-23
Registration Number : Su434-5-ND
Manufacturer Name : Jubilant Pharmova Limited
Manufacturer Address : Plot No. 18, 56, 57 & 58 KIADB Industrial Area Nanjangud - 571 302 Mysore(district), ...

Registrant Name : Masung LS Co., Ltd.
Registration Date : 2019-03-20
Registration Number : Su163-17-ND
Manufacturer Name : Lupin Limited
Manufacturer Address : Block No.21, Dabhasa Taluka Padra City : Dabhasa-391-440, Dist : Vadodara, Gujarat, s...

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2016-03-25
Registration Number : Su4749-16-ND(1)
Manufacturer Name : MSN Pharmachem Private Limit...
Manufacturer Address : Plot No.: 182 to 186 ,192-A, 193 to 197 & 212/ A,B,C,D, Phase-II, IDA Pashamylaram, P...

Registrant Name : JLBio Co., Ltd.
Registration Date : 2025-04-21
Registration Number : Su972-1-ND
Manufacturer Name : Raghava Life Sciences Privat...
Manufacturer Address : Sy.No.888 &901, Jangampally Village, Bhiknoor Mandal, Kamareddy Dist, Pin Code: 50310...

Registrant Name : ST Pharm Co., Ltd.
Registration Date : 2016-01-14
Registration Number : 5986-5-ND
Manufacturer Name : ST Pharm Co., Ltd.
Manufacturer Address : 231 Hyup-ro, Siheung-si, Gyeonggi-do

Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2024-05-29
Registration Number : Su163-19-ND(2)
Manufacturer Name : Venkata Narayana Active Ingr...
Manufacturer Address : Sy. No. 69, Chandrapadiya Village, Vinjamur Mandal, SPSR Nellore District-524228, And...

Registrant Name : Hyundai Pharmaceutical Co., Ltd.
Registration Date : 2021-05-21
Registration Number : Su163-19-ND(1)
Manufacturer Name : Venkata Narayana Active Ingr...
Manufacturer Address : Sy. No. 69, Chandrapadiya Village, Vinjamur Mandal, SPSR Nellore District-524228, And...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-060
Start Marketing Date : 2023-06-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12828-0087
Start Marketing Date : 2016-07-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 71901-611
Start Marketing Date : 2023-12-27
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65977-0075
Start Marketing Date : 2008-10-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 14445-021
Start Marketing Date : 2021-06-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER, FOR SOLUTION (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65372-1186
Start Marketing Date : 2015-01-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 50370-0024
Start Marketing Date : 2011-12-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 17205-107
Start Marketing Date : 2010-04-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 53747-069
Start Marketing Date : 2018-03-07
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 13612-0021
Start Marketing Date : 2021-01-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for partial-onset seizures in adults and in pediatric patients.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Motpoly XR
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aucta Launches MOTPOLY XR, the First Once-Daily Lacosamide Formulation
Details : Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for partial-onset seizures in adults and in pediatric patients.
Product Name : Motpoly XR
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 26, 2024
Details:
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Lacosamide-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 22, 2022
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.
Product Name : Lacosamide-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 22, 2022
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vimpat-Generic (lacosamide) is a sodium channel alpha subunit blocker, which is being evaluated for the treatment of primary generalized tonic-clonic seizures.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Vimpat-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Glenmark Pharma Arm Launches Seizure Drug in US
Details : Vimpat-Generic (lacosamide) is a sodium channel alpha subunit blocker, which is being evaluated for the treatment of primary generalized tonic-clonic seizures.
Product Name : Vimpat-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 16, 2024

Details:
Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Coma.
Lead Product(s): Lorazepam,Midazolam,Diazepam,Levetiracetam,Divalproex Sodium,Lacosamide
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Controlled Substance
Sponsor: Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2024

Lead Product(s) : Lorazepam,Midazolam,Diazepam,Levetiracetam,Divalproex Sodium,Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Coma.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 12, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lacosamide is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Beijing Capton Pharmaceutical Technology Development
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Beijing Capton Pharmaceutical Technology Development
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lacosamide is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels and possibly interacts with collapsin response mediator protein-2. It is indicated for treating partial onset seizures.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Vimpat-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Receives FDA Approval for Lacosamide Tablets 50mg, 100mg, 150mg, & 200mg
Details : Lacosamide selectively enhances slow inactivation of voltage-gated sodium channels and possibly interacts with collapsin response mediator protein-2. It is indicated for treating partial onset seizures.
Product Name : Vimpat-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 09, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Lacosamide-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
Product Name : Lacosamide-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lacosamide Tablets, USP (generic version of Vimpat), indicated for the prevention and control of seizures, enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Lacosamide-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Breckenridge Pharmaceutical
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 19, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lacosamide Tablets, USP (generic version of Vimpat), indicated for the prevention and control of seizures, enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels.
Product Name : Lacosamide-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 19, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The approval granted by U.S.FDA for ANDA of Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg, a generic version of Vimpat®2 Tablets, 50 mg, 100 mg, 150 mg and 200 mg will be used for prevention and control of seizures.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Vimpat-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval granted by U.S.FDA for ANDA of Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg, a generic version of Vimpat®2 Tablets, 50 mg, 100 mg, 150 mg and 200 mg will be used for prevention and control of seizures.
Product Name : Vimpat-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The PGTCS approval is based, in part, on results of a Phase 3 study. All three VIMPAT formulations, intravenous injections, are now indicated for the treatment of partial-onset seizures and as adjunctive therapy in the treatment of PGTCS in patients aged 4 and above.
Lead Product(s): Lacosamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Vimpat
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lacosamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
UCB's VIMPAT® CV Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded P...
Details : The PGTCS approval is based, in part, on results of a Phase 3 study. All three VIMPAT formulations, intravenous injections, are now indicated for the treatment of partial-onset seizures and as adjunctive therapy in the treatment of PGTCS in patients aged...
Product Name : Vimpat
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 17, 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info : RX
Registration Country : USA
Brand Name : LACOSAMIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 200MG/20ML (10MG/ML)
Packaging :
Approval Date : 2024-03-25
Application Number : 217718
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : Registered in EU
Registration Country : Germany
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Registered in EU
Registration Country : Germany
Regulatory Info : RX
Registration Country : USA
Brand Name : MOTPOLY XR
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 100MG
Packaging :
Approval Date : 2023-05-04
Application Number : 216185
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AP
Brand Name : LACOSAMIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 200MG/20ML (10MG/ML)
Approval Date : 2024-03-25
Application Number : 217718
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : Yes
TE Code :
Brand Name : MOTPOLY XR
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 100MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : MOTPOLY XR
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 150MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : MOTPOLY XR
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 200MG
Approval Date : 2023-05-04
Application Number : 216185
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : LACOSAMIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 150MG
Approval Date : 2022-07-12
Application Number : 205011
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LACOSAMIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2022-03-31
Application Number : 214695
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : LACOSAMIDE
Dosage Form : SOLUTION;ORAL
Dosage Strength : 10MG/ML
Approval Date : 2024-03-27
Application Number : 204839
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LACOSAMIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 100MG
Approval Date : 2023-01-05
Application Number : 204994
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AP
Brand Name : LACOSAMIDE
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 200MG/20ML (10MG/ML)
Approval Date : 2022-04-07
Application Number : 214301
RX/OTC/DISCN : RX
RLD : No
TE Code : AP

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : LACOSAMIDE
Dosage Form : TABLET;ORAL
Dosage Strength : 200MG
Approval Date : 2022-03-17
Application Number : 204921
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ACH-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 200MG
Packaging :
Approval Date :
Application Number : 2489317
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : AG-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 2501937
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : AURO-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 100MG
Packaging : 14/60/100/500
Approval Date :
Application Number : 2475340
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : JAMP-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number : 2488388
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MINT-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 2490560
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PHARMA-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 100MG
Packaging : 60
Approval Date :
Application Number : 2478218
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : SANDOZ LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 150MG
Packaging : 60
Approval Date :
Application Number : 2474697
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 2512890
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : TEVA-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 50MG
Packaging : 60
Approval Date :
Application Number : 2472902
Regulatory Info : Prescription
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : TEVA-LACOSAMIDE
Dosage Form : TABLET
Dosage Strength : 200MG
Packaging : 60
Approval Date :
Application Number : 2472937
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 388619-64-5
Quantity Per Vial :
Price ($) : 450
Catalog Number : 1A02310
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 2295925-90-3
Quantity Per Vial :
Price ($) : 1900
Catalog Number : 1A01820
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
N-Benzylacetamide (N-Acetylbenzylamine)
CAS Number : 588-46-5
Quantity Per Vial :
Price ($) : 700
Catalog Number : 1A01810
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 86921-49-5
Quantity Per Vial :
Price ($) : 700
Catalog Number : 1A01800
Current Lot : 25 mg
Previous Lot :
NDC Code :
USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.
CAS Number : 2742962-60-1
Quantity Per Vial :
Price ($) : 2000
Catalog Number : 1A01790
Current Lot : 25 mg
Previous Lot :
NDC Code :
ABOUT THIS PAGE
83
PharmaCompass offers a list of Lacosamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Lacosamide manufacturer or Lacosamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Lacosamide manufacturer or Lacosamide supplier.
PharmaCompass also assists you with knowing the Lacosamide API Price utilized in the formulation of products. Lacosamide API Price is not always fixed or binding as the Lacosamide Price is obtained through a variety of data sources. The Lacosamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lacosamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lacosamide, including repackagers and relabelers. The FDA regulates Lacosamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lacosamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lacosamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lacosamide supplier is an individual or a company that provides Lacosamide active pharmaceutical ingredient (API) or Lacosamide finished formulations upon request. The Lacosamide suppliers may include Lacosamide API manufacturers, exporters, distributors and traders.
click here to find a list of Lacosamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lacosamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Lacosamide active pharmaceutical ingredient (API) in detail. Different forms of Lacosamide DMFs exist exist since differing nations have different regulations, such as Lacosamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lacosamide DMF submitted to regulatory agencies in the US is known as a USDMF. Lacosamide USDMF includes data on Lacosamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lacosamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lacosamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lacosamide Drug Master File in Japan (Lacosamide JDMF) empowers Lacosamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lacosamide JDMF during the approval evaluation for pharmaceutical products. At the time of Lacosamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lacosamide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lacosamide Drug Master File in Korea (Lacosamide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lacosamide. The MFDS reviews the Lacosamide KDMF as part of the drug registration process and uses the information provided in the Lacosamide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lacosamide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lacosamide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lacosamide suppliers with KDMF on PharmaCompass.
A Lacosamide CEP of the European Pharmacopoeia monograph is often referred to as a Lacosamide Certificate of Suitability (COS). The purpose of a Lacosamide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lacosamide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lacosamide to their clients by showing that a Lacosamide CEP has been issued for it. The manufacturer submits a Lacosamide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lacosamide CEP holder for the record. Additionally, the data presented in the Lacosamide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lacosamide DMF.
A Lacosamide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lacosamide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lacosamide suppliers with CEP (COS) on PharmaCompass.
A Lacosamide written confirmation (Lacosamide WC) is an official document issued by a regulatory agency to a Lacosamide manufacturer, verifying that the manufacturing facility of a Lacosamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lacosamide APIs or Lacosamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Lacosamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Lacosamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lacosamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lacosamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lacosamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lacosamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lacosamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lacosamide suppliers with NDC on PharmaCompass.
Lacosamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lacosamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lacosamide GMP manufacturer or Lacosamide GMP API supplier for your needs.
A Lacosamide CoA (Certificate of Analysis) is a formal document that attests to Lacosamide's compliance with Lacosamide specifications and serves as a tool for batch-level quality control.
Lacosamide CoA mostly includes findings from lab analyses of a specific batch. For each Lacosamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lacosamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Lacosamide EP), Lacosamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lacosamide USP).